invest summari qualiti sale ep beat reiter
ow rate price target share sale growth across
oncolog vaccin anim health select hospital/specialti care product well
margin expans opportun underappreci view therefor
multipl expans upward earn revis drive share higher
 takeaway support posit thesi world-wide sale
increas sale increas exclud fx growth
driven oncolog human health vaccin sale repres
total sale perform intern market led china
pharmaceut sale repres growth yoy
exclud fx china sale grew keytruda sale grew
exclud fx sale grew human health vaccin sale grew
exclud fx sale grew keytruda combin chemo
met primari endpoint pcr pivot phase trial
neoadjuv therapi patient triple-neg breast cancer trial
continu evalu dual-primari endpoint ef result
present upcom medic congress
growth oncolog driven keytruda reflect strong momentum
nsclc indic well continu uptak indic
includ recent launch rcc adjuv melanoma indic along
growth lynparza lenvima growth vaccin reflect higher
sale gardasil gardasil primarili due public sector buy pattern
demand price on-going commerci launch china
higher demand eu driven increas vaccin rate boy
girl also contribut sale growth anim health sale increas
yoy exclud fx sale grew growth driven livestock
companion anim sale perform reflect volum growth vaccin
insulin product interest larg scale focu
organ growth bolt-on deal
 report adjust dilut ep factset
higher estim narrow rais ep guidanc
factset consensu
adjust financi model report increas
ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
arriv price target merck share use blend dcf
competit setback key product could materi neg impact
merck abil gener profit oper cash flow depend larg continu
profit compani key product januvia janumet keytruda gardasil/
gardasil isentress result compani depend key product event
advers affect product market product could
signific advers impact result oper cash flow event could
includ loss patent protect increas cost associ manufactur gener
over-the-count avail compani product competit product discoveri
previous unknown side effect result post-approv trial increas competit
introduct new more-effect treatment discontinu remov
market product reason event could materi advers effect
sale product
merck effort may succeed develop commerci success product
like major pharmaceut compani order remain competit merck must
continu launch new product year expect declin sale product
loss market exclus mean compani futur success depend pipelin
new product includ new product may develop collabor joint
ventur product abl obtain licens acquisit accomplish
compani commit substanti effort fund resourc research develop
dedic resourc variou collabor third parti
high rate failur inher research develop process new drug
result high risk fund invest merck research program
gener financi return risk profil compound fact research
long invest cycl bring pharmaceut compound discoveri phase
market may take decad failur occur point process includ
later process signific fund invest
merck could continu face price pressur respect product merck
could continu face price pressur global particularli matur market
manag care organ govern agenc program could neg affect
compani sale profit margin unit state includ practic manag
care group institut government purchas feder law regul
relat medicar medicaid includ medicar prescript drug improv
modern act state activ aim increas price
transpar chang healthcar system enact part healthcar reform
unit state well increas purchas power entiti negoti behalf
medicar medicaid privat sector beneficiari could result price pressur
addit larger custom may futur ask receiv higher rebat
drug certain highli competit categori compani must also compet place
formulari manag care organ exclus product formulari
lead reduc usag manag care organ
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casekeytrudapeak sale vaccin sale exceed expectationsoper margin expans exce expectationsnew pipelin opportun exceed scenario casekeytrudapeak sale vaccin sale line expectationsoper margin expans in-lin expectationsnew pipelin opportun in-lin scenario casekeytrudapeak sale vaccin sale expectationsoper margin expans expectationsnew pipelin opportun scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot growth driven oncolog vaccin ah growth driven livestock materi gross oper non oper pre-tax tax net incom attribut averag oper cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom aqu patent expir formul septemb injectionu patent expir septemb cv outcom studi estimate primari completionseptemb phase prep studi once-monthli oral formul low-risk infect septemb delstrigopdufa approv decis advanc rcc novemb primari complet date endometriosi decemb pneumoconjug vaccin phase estimate primari data first-lin ovarian combin profound data second-lin metastat castration-resist prostat bemcentinib trial cohort preliminari result selumetinib regulatori submiss accept pediatr neurofibromatosi registration-en data non-muscl bladder data first-lin bladder mono/combo data first-lin msi-h colorect data first-lin triple-neg breast registration-en data second-lin cutan squamou cell data first-lin extens stage small cell lung cancer decis bemcentinib trial cohort second stage data medic phase data upcom medic congress neoadjuvant/adjuv imipenem/cilastatin imi/rel phase data patent patent patent roll bla submiss ebola aqeu patent expir aqjapan patent expir patent expirationsourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom estimate primari complet date heart failur januari pneumoconjug vaccin phase estimate primari completionfebruari date sbla dose februari pneumoconjug vaccin phase estimate primari complet march pneumoconjug vaccin phase estimate primari completionmay patent expir combin juli pneumoconjug vaccin phase estimate primari complet juli stay expir juli estimate primari complet chronic cough august pneumoconjug vaccin phase estimate primari complet octob estimate primari complet hiv infect combin safeti primari object decemb estimate primari complet metastat castration-resist prostat cancer decemb pneumoconjug vaccin phase estimate primari complet decemb estimate primari complet date second-lin nsclc stage nrdl list studi data first-lin renal cell cancer data second-lin nasopharyng patent expir injectioneu patent injectionjapan patent patent expir method pediatr hexaval combin vaccin patent expir method pediatr hexaval combin vaccin avail commerci suppli januari estimate primari complet chronic cough januari pneumoconjug vaccin phase estimate primari complet februari pneumoconjug vaccin phase ped estimate primari complet april propel estimate primari complet mcrpc estimate primari complet respiratori synctial viru may cytomegaloviru cmv vaccin phase estimate primari complet june keytrudaphas estimate primari complet melanoma septemb docetaxel prednisonephas estimate primari complet mcrpc octob lynparzaphas estimate primari complet mcrpc novemb pneumoconjug vaccin phase estimate primari data readout nsclc data readout hnscc patent expir februari estimate primari complet advanc endometri cancer march biopharmaceuticalsend research phase strateg collabor option extend addit year march estimate primari complet nsclc may estimate primari complet advanc non-smal cell lung cancer juli estimate primari complet combo juli patent expirationjuli patent expirationjuli xru patent data readout mibc local data readout data readout adjuv data readout rcc patent patent patent patent expir decemb estimate primari complet urotheli cancer data readout hnscc local data readout gastric esophag patent patent ebola vaccin patent selumetinib patent expir august keytruda chemophas estimate primari complet nonsq nsclc august monotherapi keytruda phase estimate primari complet nonsq nsclc novemb enzalumatidephas estimate primari complet mcrpc decemb primari complet date relaps refractori classic hodgkin patent spc patent spc expirationsourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom patent expir april estimate primari complet melanoma may estimate primari complet sq nsclc august estimate primari complet nonsq data readout nsclc patent patent patent patent spc patent spc patent expir august estimate primari complet patent expir devic septemb estimate primari complet neoadjuvant/adjuv first-lin triple-neg breast data readout adjuvant/neoadjuv data readout adjuvant/neoadjuv data readout nsclc stage data readout patent patent spc patent spc expirationjanuari patent expir pend decemb patent data readout tnbc data readout cscc local data readout breast cancer adjuvant/neoadjuv june patent expir pend septemb patent expir patent expirationfebruari patent expirationapril patent expir pend may patent expir pend june patent expirationjun patent expirationjun patent patent spc patent expirationnovemb patent patent expir pend relebactam imipenem/cilastatin patent patent spc expirationmay patent patent patent expir pend patent expir pend patent expir pend doravirin patent doravirine/lamivudine/tenofovir disoproxil fumar patent patent patent patent expir pend sourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
fitzgerald million except per share oper expenseshigh mid-singl digit effect tax cantor fitzgerald research compani quarterli result reinforc confid compani drive sustain long-term revenu growth meaning oper margin expans maintain disciplin capit alloc strategi focus invest return capit higher revenu driven global oncolog vaccin sale exposur first-lin set indic keytruda drive forc penetr segment popul includ low express patient continu recent measl outbreak lead vaccin growth addit higher adopt global believ continu see growth pediatr vaccin go china expect largest ou market keytruda show growth gardasil uptak gross margin increas bp yoy affect catchup adjust accru sale mileston relat expect mostli flat due neg price go forward impact royalti step-down impact livestock grew primarili due product acquir antelliq companion anim volum growth vaccin insulinproduct partial off-set time custom purchs prior year updat guidanc rang assum measur impact foreign exchang mid-juli opex expect increas mid-singledigit primarili driven expens expect take bolt-on acquisit larg merger state defin dollar expect brisk pace regulatori approv jurisd achiev continu especi oncolog regard nuvar perform gener entri quarter continu promot nuvar done guidanc revis increas narrow revenu expect yoy ex-fx non-gaap ep yoy ex-fx non-gaap oper expens expect increas mid expect see growth pediatr vaccin go forward see buy-in anticip come ad indic growth strong data adopt ou oncolog market may outpac market lynparza growth driven uptak ovarian cancer strength eu china japan lynparza continu tolead parpi class nearli total patient share lenvima growth driven sale china launch insever gardasil growth driven public sector purchas greater demand adolesc cohort well continu demand across euand emerg market especi china cdc purchas made took place last year see strong demand especi year old cohort year old cohort ex-u demand also strong particular china euwith gender neutral program roll would character growth look ytd growth bridion annual reflect strong perform bridion continu increas share within revers lynparza goe part keytruda reimburs part china sale grow yoy driven number product lynparza lenvima keytruda gardasil believ continu see declin price impact margin margin factor includ royalti reduct keytrudato nc impact collabor near-term drag margin long-term may becom wait see keytruda invit particip china nrdl next year nrdl would expand popul chinafairli significantli lung cancer patient china part label indic exhibit incom statement analysi
million except per share amount compound-annual-growth-rate year end decemb gener oper incom attribut share dilut changetot gener incom attribut share dilut cantor fitzgerald research compani report includ exchang loss equiti incom loss affili net period defin benefit plan credit cost servic cost net amount adjust acquisit divestiture-rel cost certain item acquisit divestiture-rel cost expens amort intang asset recogn result acquisit amort purchas account adjust inventori relat acquisit inc intang asset impair charg integr transact certain cost relat busi acquisit includ sever cost part compani formal restructur program well transact certain cost relat busi divestitur in-process research develop ipr impair charg reduct expens result decreas estim fair valu liabil conting consider goodwil impair charg relat certain busi within segment restructur cost primarili includ employe separ cost acceler depreci associ facil close divest relat activ compani formal restructur program certain item primarili reflect foreign exchang loss devalu compani net monetari asset venezuela net charg settl vioxx sharehold class action litig gain divestitur certain migrain clinic develop program gain divestitur compani remain ophthalm busi intern market relat tax effect exclud acquisit divestiture-rel cost expens amort intang asset recogn result busi acquisit intang asset impair charg integr transact certain cost relat busi acquisit divestitur ipr impair charg expens relat increas estim fair valu measur liabil conting consider goodwil intang asset impair charg relat busi segment well expens relat chang estim fair valu measur liabil conting consider partial off-set royalti incom connect termin sanofi-pasteur msd joint ventur restructur cost primarili includ employe separ cost acceler depreci associ facil close divest relat activ compani formal restructur program certain item includ aggreg charg record conjunct format collabor astrazeneca relat tax effect exclud acquisit divestiture-rel cost amort intang asset recogn result busi acquisit integr transact certain cost relat busi acquisit divestitur ipr impair charg partial off-set reduct expens relat decreas estim fair valu measur liabil conting consider goodwil impair charg relat certain busi segment increas estim fair valu measur liabil conting consider partial off-set royalti incom relat termin sanofi-pasteur msd joint ventur restructur cost employe separ cost acceler depreci associ facil close divest relat activ compani formal restructur program certain item relat tax effect exclud acquisit divestiture-rel cost expens amort intang asset recogn result busi acquisit reduct expens relat net decreas estim fair valu measur liabil conting consider goodwil impair charg relat certain businessesin segment partial off-set royalti incom relat termin sanofi-pasteur msd joint ventur restructur cost employe separ cost acceler depreci associ facil close divest relat activ compani formal restructur program certain item includ million net tax benefit relat settlement certain feder incom tax matter million tax charg relat final treasuri regul associ enact tax legisl relat tax effect exclud expens amort intang asset recogn result busi acquisit well intang asset impair charg integr transact certain cost relat busi acquisit divestitur includ cost relat acquisit antelliq corpor goodwil impair charg relat certain busi segment expens relat increas estim fair valu liabil conting consider relat termin sanofi-pasteur msd joint ventur employe separ cost acceler depreci associ facil close divest relat activ compani formal restructur program relat tax effect exhibit margin analysi
exhibit quarterli sale analysi
million year end decemb hospit acut immunology- women diversifi total hospit acut women diversifi vericiguat total pipeline- total anim health total anim anim health anim total anim revenu total changeu acut acut anim healthtot anim anim health anim anim cantor fitzgerald research compani report separ belsomra atozet adempa sale atozet market certain countri outsid lead commerci right adempa countri outsid america merck began promot distribut adempa europ merck record sale adempa separ livestock companion anim revenu compris primarili segment revenu third-parti manufactur sale miscellan corpor revenu includ revenu hedg activ exhibit annual sale analysi
end decemb acut acut pharmaceut pipeline- anim health total anim anim health anim anim revenu cantor fitzgerald research compani report separ belsomra sale belsomra sale includ number belsomra estim separ livestock companion anim number livestock companion anim estim revenu compris primarili segment revenu third-parti manufactur sale miscellan corpor revenu includ revenu hedg activ year end decemb exhibit analysi
million decemb fiscal oper activitynet incom alloc non-controlling depreci chang oper asset net oper invest activ capit purchas secur proce sale secur acquisit busi net cash disposit busi net cash divested- net invest financ activitiesnet chang short-term payment proce issuanc debt- purchas treasuri dividend paid proce exercis stock net financ effect exchange-r chang cash cash net increas decreas cash cash equival equival sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million decemb fiscal assetscash cash short-term account receiv current total current pp cost less accumul intang total liabil sharehold equitycurr liabilitiesloan payabl current portion long-term trade account accru current incom tax dividend total current long-term defer incom non-current total sharehold equitycommon paid-in retain accumul comprehens less treasuri stock total sharehold non-controlling total total liabili sourc cantor fitzgerald research compani report juli
merck co inc global healthcar compani deliv innov health solut prescript medicin vaccin
biolog therapi anim health product compani oper includ four oper segment anim health
allianc segment segment includ human health pharmaceut vaccin product
health pharmaceut product consist therapeut prevent agent gener sold prescript treatment
human disord anim health segment discov develop manufactur market anim health product includ vaccin
compani segment provid servic solut focu engag health analyt clinic servic
improv valu care deliv patient compani incorpor new jersey
